Sanae Namiki
Papers
5
Total Citations
40
H-Index
4
About
Dr. Sanae Namiki is a Japanese urologic surgeon and clinical researcher whose work focuses on optimizing surgical and multimodal treatment strategies for prostate and bladder cancers. Her major contributions center on robot-assisted radical prostatectomy (RARP), particularly in high-risk and very-high-risk prostate cancer patients. In a landmark multicenter study (the MSUG94 Group, 15 citations), Dr. Namiki challenged conventional practice by demonstrating that pelvic lymph node dissection may not improve biochemical recurrence-free survival in Japanese patients undergoing RARP—a finding with significant implications for reducing surgical morbidity. She has also pioneered neoadjuvant chemohormonal therapy protocols, combining LHRH antagonists with tegafur-uracil to improve outcomes in high-risk disease (5 citations), and validated standardized training systems for RARP that enable novice surgeons at low-volume centers to achieve outcomes comparable to experienced surgeons (9 citations). Her case report on enfortumab vedotin for metastatic urothelial carcinoma highlights her work in advanced bladder cancer. With over 40 total citations and a growing portfolio of prospective studies, Dr. Namiki is establishing herself as a leading voice in evidence-based, minimally invasive urologic oncology in Japan.
Research Focus
Key Achievements
Top Papers
- 1
- 2
- 3
- 4
- 5